Sagar Lonial, MD
Professor and Chair, Hematology & Medical Oncology
Emory University School of Medicine
Chief Medical Officer
Winship Cancer Institute of Emory University
Office: Winship Cancer Institute of Emory University
Phone: (404) 778-3921
Fax: (404) 778-5530
Dr. Sagar Lonial is internationally recognized as a leading authority in multiple myeloma treatment and research. A Board certified hematologist and medical oncologist, Dr. Lonial staffs and works both on the transplant service as well as in the B-cell malignancy clinic.
Dr. Lonial completed his Hematology-Oncology training at Emory University, and prior to that received his internal medicine residency at the Baylor College of Medicine in Houston Texas. There he spent an additional year as a Chief Medical Resident at the Ben Taub General Hospital as well as the Texas Heart Institute and St. Lukes Hospital.
Dr. Lonial is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. He serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the board of directors for the International Myeloma Society, and on the scientific Advisory Board for the International Myeloma Foundation. He is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University.
Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and in the previous 3 years has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. Dr. Lonial's previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen, and he has completed several trials evaluating the impact of cytokines on dendritic cell content and post transplant immune recovery. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. His lab has recently received funding from the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation, and The Leukemia & Lymphoma Society.
- View publications on Pubmed
Dr. Lonial has authored or coauthored over 200 publications and in addition, he serves on the editorial board of the Journal of Clinical Oncology, Leukemia, and is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia, and as an invited or ad hoc reviewer for several publications, including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others.
View clinical trials at Winship Cancer Institute